Biocartis' KRAS Mutation Test Receives CE-IVD Mark | GenomeWeb

NEW YORK (GenomeWeb) – Biocartis today announced its Idylla KRAS Mutation Test has received CE-IVD marking. 

The Belgian company has launched the sample-to-result test for the detection of 21 relevant mutations in the KRAS oncogene. It is the first fully automated CE-IVD test available for routine use and detects all clinically relevant driver mutations of the KRAS oncogene in tissue of colorectal cancers at a 5 percent sensitivity rate, Biocartis said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.